
Insilicon Received D2 Round Of Financing
On August 10, Insilicon, a clinical-stage drug development company driven by end-to-end artificial intelligence, announced today that it has received a D2 round of financing.
On August 10, Insilicon, a clinical-stage drug development company driven by end-to-end artificial intelligence, announced today that it has received a D2 round of financing.